Clinical trialNCT07202546RecruitingPhase 2Interventional

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

SponsorViiV HealthcareEnrollment186HIV Infections

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

123 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Buenos Aires, Argentina
Veronica Lacal Ridilenir
Recruiting
Gsk Investigational Site
Buenos Aires, Argentina
Pedro Cahn
Recruiting
Gsk Investigational Site
Buenos Aires, Argentina
Guillermina Maria Roveda Vergés
Recruiting
Gsk Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
Gustavo Lopardo
Recruiting
Gsk Investigational Site
Ciudad Autonoma de Bueno, Argentina
Ezequiel Cordova
Recruiting
Gsk Investigational Site
Mar del Plata, Argentina
Gonzalo Corral
Recruiting
Gsk Investigational Site
San Miguel de Tucumán, Argentina
Juan Gonzalo Tomas
Recruiting

Australia

Gsk Investigational Site
Sydney, New South Wales, Australia
Mark Bloch
Recruiting
Gsk Investigational Site
Clayton, Victoria, Australia
Ian Woolley
Recruiting
Gsk Investigational Site
Melbourne, Victoria, Australia
James McMahon
Recruiting

Belgium

Gsk Investigational Site
Antwerp, Belgium
Jelle Visser
Recruiting
Gsk Investigational Site
Brussels, Belgium
Martin Vandeputte
Recruiting
Gsk Investigational Site
Ghent, Belgium
Marie-Angélique De Scheerder
Recruiting

Canada

Gsk Investigational Site
Montreal, Quebec, Canada
Joseph Cox
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Jason Szabo
Recruiting

France

Gsk Investigational Site
Bordeaux, France
Fabrice Bonnet
Recruiting
Gsk Investigational Site
Caen, France
Jean-Jacques PARIENTI
Recruiting
Gsk Investigational Site
Nantes, France
Colin Deschanvres
Recruiting
Gsk Investigational Site
Nîmes, France
Paul Loubet
Recruiting
Gsk Investigational Site
Paris, France
karine lacombe
Recruiting
Gsk Investigational Site
Paris, France
Valérie POURCHER
Recruiting

Germany

Gsk Investigational Site
Berlin, Germany
Hartmut Stocker
Recruiting
Gsk Investigational Site
Cologne, Germany
Clara Lehmann
Recruiting
Gsk Investigational Site
Frankfurt, Germany
Christoph Stephan
Recruiting
Gsk Investigational Site
Hamburg, Germany
Christian Hoffmann
Recruiting
Gsk Investigational Site
München, Germany
Sebastian Noe
Recruiting

Italy

Gsk Investigational Site
Bergamo, Italy
Diego Ripamonti
Recruiting
Gsk Investigational Site
Milan, Italy
Andrea Gori
Recruiting
Gsk Investigational Site
Milan, Italy
Giulia Carla Marchetti
Recruiting
Gsk Investigational Site
Milan, Italy
Antonella Castagna
Recruiting
Gsk Investigational Site
Milan, Italy
Alessandra Bandera
Recruiting
Gsk Investigational Site
Roma, Italy
Carlo Torti
Recruiting
Gsk Investigational Site
Roma, Italy
Andrea Antinori
Recruiting

Japan

Gsk Investigational Site
Fukuoka, Japan
Rumi Minami
Recruiting
Gsk Investigational Site
Kanagawa, Japan
Yukihiro Yoshimura
Recruiting
Gsk Investigational Site
Okinawa, Japan
Hideta Nakamura
Recruiting
Gsk Investigational Site
Osaka, Japan
Michinori Shirano
Recruiting
Gsk Investigational Site
Osaka, Japan
Dai Watanabe
Recruiting
Gsk Investigational Site
Tokyo, Japan
Eisuke Adachi
Recruiting
Gsk Investigational Site
Tokyo, Japan
Ei Kinai
Recruiting

83 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dolutegravir →Emtricitabine and tenofovir alafenamide Fixed Dose Combination tabletsVH4524184

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Feb 2026
Primary completion: 11 Jun 2027
Completion: 22 May 2028
Last update posted: 23 Jul 2026
Registered enrollment: 186
Registry id: NCT07202546

Cross-registrations

EU-CTR / CTIS (EudraCT)2025-521918-26-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.